Nanoligent is a preclinical stage biotech company based in Barcelona developing a new targeted antimetastatic drug. We are developing precision nanomedicines that selectively kill metastatic tumor cells overexpressing the CXCR4 receptor. CXCR4 is a widely researched topic in oncology but without a winning therapy yet. Nanoligent is uniquely and differentially positioned to deliver a therapeutic treatment option. We have very promising results in several animal models and we are raising capital to take our first candidate to the clinical stage.